The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma...
المؤلفون الرئيسيون: | Cesca, M, Frapolli, R, Berndt, A, Scarlato, V, Richter, P, Kosmehl, H, D'Incalci, M, Ryan, A, Giavazzi, R |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2009
|
مواد مشابهة
-
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
حسب: Edmond Auzenne, وآخرون
منشور في: (2007-06-01) -
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
حسب: Wachsberger, P, وآخرون
منشور في: (2009) -
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
حسب: Choi, S, وآخرون
منشور في: (2008) -
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
حسب: Demuytere J, وآخرون
منشور في: (2024-01-01) -
Modulation of gene expression associated with copy number variation identifies key regulatory programs in high-grade serous ovarian carcinoma
حسب: Martina Vescio, وآخرون
منشور في: (2023-07-01)